Abstract

A LITERATURE REVIEW ON THE DRUG PROFILE OF DEUCRAVACITINIB

*T. Khasid, Dr. B. V. Ramana, Dr. S. Kusuma Kumari

ABSTRACT

Context: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, inhibits cytokine signaling in psoriasis pathogenesis. The safety of SOTYKTU was evaluated in two placebo, active-controlled trails and open label extention trail. Objective: The purpose of this study is to provide an overview of the data that is currently available about the discovery, pharmacokinetics, pharmacodynamics, safety and effectiveness of deucravacitinib. Methods: To find pertinent studies on the usage of deucravacitinib, we explored pubMed, Embase and worldwide pharmaceutical abstracts. A search of clinical trails registries was also conducted. Conclusion: Deucravacitinib demonstrated superiority versus placebo and apremilast and was well tolerated in adults with moderate to severe plaque psoriasis. It has the potential to become a promising new oral therapy.

Keywords: Clinical trial; deucravacitinib; efficacy; psoriasis; safety; skin diseases; tyrosine kinase 2; quality of life (QOL); cytokines.